510(k) Report

510(k) · Cleared

Cleared

Refobacin Bone Cement R

K150850510(k) TraditionalCleared Jul 16, 2015107-day reviewClass II21 CFR 888.3027

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Biomet, Inc. · MBB Bone Cement, Antibiotic

Cleared on Jul 16, 2015 as substantially equivalent to K031673 (Heraeus Kulzer GmbH & Co. KG, 2004) after a 107-day review. Its family tree reaches back 2 generations to 1984.

Decided
Jul 16, 2015
Review
107 days
Class
Class II
Product code
MBB
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to P810020 (1984). No later device cites it as a predicate yet.

  1. Root · 2 generations backP810020 Palacos R Bone CementSmith & Nephew Richards, Inc. · 1984 · Recalled
  2. 1 generation backK031673 Refobacin -Palacos GHeraeus Kulzer GmbH & Co. KG · 2004 · Recalled
  3. This deviceK150850 Refobacin Bone Cement RBiomet, Inc. · 2015
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2P810020Palacos R Bone CementSmith & Nephew Richards, Inc.19841
−1K031673Refobacin -Palacos GHeraeus Kulzer GmbH & Co. KG20041
0 (this device)K150850Refobacin Bone Cement RBiomet, Inc.2015—
FIG. 1 — Lineage of K150850, 1984–2015Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MBB? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MBB device

  1. #1 K252443 SpaceFix Shoulder Spacerscore 12.4 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K031673Refobacin -Palacos G
Summary page 4
…KIH– Optipac®- Refobacin® Bone Cement R (21 CFR 888.4200) Legally marketed devices to which substantial equivalence is claimed: PALACOS®G Bone Cement (K031673)* *The product obtained for testing and labeling comparison is labeled as Palacos® R+G Reference Device PALACOS®R…
Heraeus Kulzer GmbH & Co. KG20041
†K142157Palacos R+G ProHeraeus Medical GmbH2014—

Also cleared against K031673: 8 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 31 years and passes through 3 companies; a new generation was cleared every 20.3 years on median.
  • 2 of the 2 ancestors have a recall of any class.
  • 8 other devices also cite its predicate K031673.

How does its category compare?

All MBB devices

MBB Bone Cement, Antibiotic: FDA decisions, review times, recalls and adverse event reports over 20 years. 2015, this device’s year, is highlighted.

FDA decisions per year · MBB

1in 2025

2007: 12008: 12014: 12015: 12016: 22017: 12019: 22020: 12021: 12022: 32024: 22025: 1
2007high 3 (2022) · low 0 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MBB

106in 2022

2022: 106 days median
2007high 106 (2022)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MBB

1in 2022

2013: 22022: 12026 (partial year): 2
2007high 2 (2013) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MBB

172in 2025

2007: 12008: 32009: 92010: 182011: 312012: 342013: 322014: 412015: 202016: 3272017: 2882018: 3322019: 4972020: 3752021: 6492022: 2752023: 2622024: 2122025: 172
2007high 649 (2021) · low 1 (2007)2025

MAUDE reports naming product code MBB, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—01
20081—03
20090—09
20100—018
20110—031
20120—034
20130—232
20141—041
20151—020
20162—0327
20171—0288
20180—0332
20192—0497
20201—0375
20211—0649
202231061275
20230—0262
20242—0212
20251—0172
20260—2—

What is it indicated for?

Refobacin Bone Cement R is indicated for use as bone cement in arthroplasty procedures of the hip, knee, and other joints to fix plastic and metal prosthetic parts to living bone when reconstruction is necessary because of revision of previous arthroplasty procedures due to joint infection. The cement is indicated for use in the second stage of a two stage revision for total joint arthroplasty after the initial infection has been cleared.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K150850: Refobacin Bone Cement R.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K150850

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026